Jean Christophe Plantier

Summary

Country: France

Publications

  1. ncbi Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG
    Jean-Christophe Plantier
    Laboratoire de Virologie, Equipe d'Accueil 2639, , Tours, France
    J Clin Microbiol 40:1010-22. 2002
  2. ncbi HIV-1 resistance genotyping on dried serum spots
    Jean Christophe Plantier
    Unité de virologie, Laboratoire associé au Centre National de Référence du VIH, Equipe d accueil 2656, CHU Charles Nicolle, Rouen, France
    AIDS 19:391-7. 2005
  3. ncbi HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef
    Daniel Sauter
    Institute of Molecular Virology, Ulm University Medical Center, 89069, Ulm, Germany
    Retrovirology 8:103. 2011
  4. ncbi Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections
    J C Plantier
    Laboratoire de Virologie and Laboratoire associé au Centre National de Référence du VIH, Institut de Biologie Clinique, Hopital Charles Nicolle, CHU de Rouen, 1 rue de Germont, 76031 Rouen, France
    J Clin Microbiol 47:2906-11. 2009
  5. ncbi A new human immunodeficiency virus derived from gorillas
    Jean Christophe Plantier
    Laboratoire Associé au Centre National de Référence du Virus de l Immunodéficience Humaine, Equipe d Accueil EA2656, Faculte de Medecine Pharmacie, Universite de Rouen, France
    Nat Med 15:871-2. 2009
  6. ncbi Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCR
    Jean Christophe Plantier
    Unité de virologie, Laboratoire associé au Centre National de Référence du VIH, Equipe d accueil 2656, CHU Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Clin Microbiol 42:5866-70. 2004
  7. ncbi Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M
    Agnès Depatureaux
    Laboratoire associé au Centre National de Référence du VIH, CHU de Rouen, Rouen, France
    J Acquir Immune Defic Syndr 56:139-45. 2011
  8. ncbi Plasma RNA quantification and HIV-1 divergent strains
    Jean Christophe Plantier
    Laboratoire de Virologie, GRAM IFR 23 CHU Charles Nicolle, Rouen, France
    J Acquir Immune Defic Syndr 33:1-7. 2003
  9. ncbi Plasma viral RNA assay in HIV-1 group O infection by real-time PCR
    Marie Gueudin
    Laboratoire de Virologie, Hopital Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Virol Methods 113:43-9. 2003
  10. ncbi Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide
    Agnès Depatureaux
    Laboratoire associé au Centre National de Référence du VIH, EA2656, CHU Charles Nicolle, Rouen, France
    Antimicrob Agents Chemother 54:4016-9. 2010

Collaborators

Detail Information

Publications31

  1. ncbi Development and evaluation of a DNA enzyme immunoassay method for env genotyping of subtypes A through G of human immunodeficiency virus type 1 group M, with discrimination of the circulating recombinant forms CRF01_AE and CRF02_AG
    Jean-Christophe Plantier
    Laboratoire de Virologie, Equipe d'Accueil 2639, , Tours, France
    J Clin Microbiol 40:1010-22. 2002
    ..This method can be adapted to the local situation by including only probes that correspond to the prevalent strains...
  2. ncbi HIV-1 resistance genotyping on dried serum spots
    Jean Christophe Plantier
    Unité de virologie, Laboratoire associé au Centre National de Référence du VIH, Equipe d accueil 2656, CHU Charles Nicolle, Rouen, France
    AIDS 19:391-7. 2005
    ....
  3. ncbi HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef
    Daniel Sauter
    Institute of Molecular Virology, Ulm University Medical Center, 89069, Ulm, Germany
    Retrovirology 8:103. 2011
    ..Here, we examined how long Group P may have been circulating in humans and determined its capability to antagonize human tetherin as an indicator of adaptation to humans...
  4. ncbi Census and analysis of persistent false-negative results in serological diagnosis of human immunodeficiency virus type 1 group O infections
    J C Plantier
    Laboratoire de Virologie and Laboratoire associé au Centre National de Référence du VIH, Institut de Biologie Clinique, Hopital Charles Nicolle, CHU de Rouen, 1 rue de Germont, 76031 Rouen, France
    J Clin Microbiol 47:2906-11. 2009
    ..This study highlights the complexity of screening for these divergent variants and the need to evaluate test performance with a large panel of strains, due to the extensive diversity of group O variants...
  5. ncbi A new human immunodeficiency virus derived from gorillas
    Jean Christophe Plantier
    Laboratoire Associé au Centre National de Référence du Virus de l Immunodéficience Humaine, Equipe d Accueil EA2656, Faculte de Medecine Pharmacie, Universite de Rouen, France
    Nat Med 15:871-2. 2009
    ..This new virus seems to be the prototype of a new HIV-1 lineage that is distinct from HIV-1 groups M, N and O. We propose to designate it HIV-1 group P...
  6. ncbi Rapid discrimination between human immunodeficiency virus type 2 groups A and B by real-time PCR
    Jean Christophe Plantier
    Unité de virologie, Laboratoire associé au Centre National de Référence du VIH, Equipe d accueil 2656, CHU Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Clin Microbiol 42:5866-70. 2004
    ..3% of group A or B samples; isolate H was not detected. This method allowed rapid and specific discrimination between HIV-2 groups A and B and could be a useful tool for molecular epidemiological studies...
  7. ncbi Impact of HIV-1 group O genetic diversity on genotypic resistance interpretation by algorithms designed for HIV-1 group M
    Agnès Depatureaux
    Laboratoire associé au Centre National de Référence du VIH, CHU de Rouen, Rouen, France
    J Acquir Immune Defic Syndr 56:139-45. 2011
    ....
  8. ncbi Plasma RNA quantification and HIV-1 divergent strains
    Jean Christophe Plantier
    Laboratoire de Virologie, GRAM IFR 23 CHU Charles Nicolle, Rouen, France
    J Acquir Immune Defic Syndr 33:1-7. 2003
    ..In conclusion, the authors showed that the LCx kit allowed quantification of the large group M diversity and group O variants...
  9. ncbi Plasma viral RNA assay in HIV-1 group O infection by real-time PCR
    Marie Gueudin
    Laboratoire de Virologie, Hopital Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Virol Methods 113:43-9. 2003
    ..Despite the high initial cost of acquiring the required cycling device, the per-sample cost of this real-time quantitative PCR assay for HIV-1 group O is low, making it suitable for use in endemic zones...
  10. ncbi Baseline genotypic and phenotypic susceptibilities of HIV-1 group O to enfuvirtide
    Agnès Depatureaux
    Laboratoire associé au Centre National de Référence du VIH, EA2656, CHU Charles Nicolle, Rouen, France
    Antimicrob Agents Chemother 54:4016-9. 2010
    ..Enfuvirtide could therefore potentially be used in antiretroviral treatments for HIV-O-infected patients...
  11. ncbi A new real-time quantitative PCR for diagnosis and monitoring of HIV-1 group O infection
    Marie Gueudin
    Laboratoire associé au Centre National de Référence du VIH, Hopital Charles Nicolle, CHU de Rouen, Rouen, France
    J Clin Microbiol 50:831-6. 2012
    ..Its detection limit is equivalent to that of commercial kits. This assay is cheap and suitable for use in areas in which strains of HIV-1 groups M and O cocirculate...
  12. ncbi A new quantitative HIV load assay based on plasma virion reverse transcriptase activity for the different types, groups and subtypes
    Josephine Braun
    Laboratoire de Virologie, Biostatistique, Centre Hospitalier Charles Nicolle, 1 rue de Germont, 76031 Rouen Cedex, France
    AIDS 17:331-6. 2003
    ..In developing countries, viral load assay is either unaffordable or hindered by on-site maintenance and/or technical problems...
  13. ncbi Evaluation of the Roche Cobas TaqMan and Abbott RealTime extraction-quantification systems for HIV-1 subtypes
    Marie Gueudin
    Laboratoire de Virologie, Equipe d accueil 2656, Centre Hospitalier Universitaire Charles Nicolle, 1 rue de Germont, 76031 Rouen, France
    J Acquir Immune Defic Syndr 44:500-5. 2007
    ..We also tested 88 plasma samples from patients infected with HIV-1 group M (B-D [n = 7], A-CRF01 [n = 16], CRF02 [n = 49], and other strains [n = 16])...
  14. ncbi Circulation of multiple patterns of unique recombinant forms B/CRF02_AG in France: precursor signs of the emergence of an upcoming CRF B/02
    Marie Leoz
    Laboratoire associé au CNR du VIH, Hopital Ch Nicolle, CHU de Rouen, France
    AIDS 25:1371-7. 2011
    ..The high prevalence and co-circulation of B and CRF02_AG strains in this population raise the possibility that recombinant forms might emerge and spread...
  15. ncbi Phenotypic susceptibility to nonnucleoside inhibitors of virion-associated reverse transcriptase from different HIV types and groups
    Edouard Tuaillon
    Laboratoire de Virologie, Centre Hospitalier Charles Nicolle, Rouen, France
    J Acquir Immune Defic Syndr 37:1543-9. 2004
    ..It would be particularly useful for large epidemiologic survey of the natural HIV polymorphism and the potential impact in emergence of drug resistance, particularly to nevirapine, widely used to prevent mother-to-child transmission...
  16. ncbi Molecular epidemiology of hepatitis B virus in Dakar, Sénégal
    Muriel Vray
    Unité d Epidémiologie des Maladies Emergentes, Institut Pasteur, Paris, France
    J Med Virol 78:329-34. 2006
    ..These results underline the importance of molecular characterization of HBV infection as specific treatments become available in this region...
  17. ncbi Virologic diagnosis and follow-up of children born to mothers infected by HIV-1 group O
    Marie Gueudin
    J Acquir Immune Defic Syndr 36:639-41. 2004
  18. ncbi HIV-1 group M superinfection in an HIV-1 group O-infected patient
    Jean-Christophe Plantier
    AIDS 18:2444-6. 2004
  19. ncbi French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002
    Diane Descamps
    Laboratoire de Virologie, CHU Bichat Claude Bernard, Paris, France
    J Acquir Immune Defic Syndr 38:545-52. 2005
    ..To survey the frequency of genotypic antiretroviral resistance and the spread of non-B subtypes in patients with primary HIV-1 infection (2001-2002) and in treatment-naive chronically HIV-1-infected patients (2001)...
  20. ncbi Integrase polymorphism and HIV-1 group O diversity
    Marie Leoz
    AIDS 22:1239-43. 2008
  21. ncbi Monitoring of HIV-1 resistance in Tunisia (North Africa) with a dried plasma spot strategy
    Raoudha Dachraoui
    J Acquir Immune Defic Syndr 47:522-5. 2008
  22. ncbi Differences in proviral DNA load between HIV-1- and HIV-2-infected patients
    Marie Gueudin
    Laboratoire de Virologie, CHU Charles Nicolle Rouen, France
    AIDS 22:211-5. 2008
    ....
  23. ncbi Human immunodeficiency virus serotyping on dried serum spots as a screening tool for the surveillance of the AIDS epidemic
    Francis Barin
    Universite Francois Rabelais, Centre National de Référence du VIH and Inserm Espri EA 3856, Tours, France
    J Med Virol 78:S13-8. 2006
    ....
  24. ncbi Plasma virion reverse transcriptase activity and heat dissociation-boosted p24 assay for HIV load in Burkina Faso, West Africa
    Jean Pierre Lombart
    , Ouagadougou, Burkina Faso
    AIDS 19:1273-7. 2005
    ..HDB-p24 use requires further evaluation before being considered as an alternative method in African HIV-infected patient follow up...
  25. ncbi Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test
    Francois Rouet
    Laboratoire de Virologie, Centre Muraz, BP 390 Bobo Dioulasso 01, Burkina Faso
    J Acquir Immune Defic Syndr 45:380-8. 2007
    ..Addressing HIV-1 diversity, continual monitoring of HIV-1 RNA assays, together with molecular epidemiology studies, is required to improve the accuracy of all HIV RNA assays...
  26. ncbi Monitoring the dynamics of the HIV epidemic using assays for recent infection and serotyping among new HIV diagnoses: experience after 2 years in France
    Caroline Semaille
    Institut de Veille Sanitaire, Saint Maurice, 94 415, France
    J Infect Dis 196:377-83. 2007
    ..New tools to better monitor dynamics of human immunodeficiency virus (HIV) transmission are needed...
  27. ncbi Prevalence of HIV-1 drug resistance in treated patients: a French nationwide study
    Dominique Costagliola
    INSERM, Unité Mixte de Recherche UMR S 720, Universite Pierre et Marie Curie Paris 6, Paris, France
    J Acquir Immune Defic Syndr 46:12-8. 2007
    ..Surveillance of HIV-1 drug resistance in antiretroviral-treated patients is important from the public health perspective of the spread of resistance and to evaluate the proportion of patients for whom new drugs are needed...
  28. ncbi HIV-1-infected patients from the French National Observatory experiencing virological failure while receiving enfuvirtide
    Diane Descamps
    AP HP, Groupe Hospitalier Bichat Claude Bernard, Laboratoire de Virologie, Paris F 75018, France
    J Antimicrob Chemother 62:451-5. 2008
    ..We studied gp41 mutations associated with failing enfuvirtide salvage therapy...
  29. ncbi Unequal detection of HIV type 1 group O infection by simple rapid tests
    Agnes Gautheret-Dejean
    Clin Infect Dis 46:1936-7. 2008
  30. ncbi Generic screening test for HIV infection
    Jean-Christophe Plantier
    AIDS 20:1345-7. 2006
  31. ncbi Comparison of hepatitis C virus NS5b and 5' noncoding gene sequencing methods in a multicenter study
    Syria Laperche
    , , Institut National de la Transfusion Sanguine, 6 rue Alexandre-Cabanel, 75015 Paris, France
    J Clin Microbiol 43:733-9. 2005
    ....